Search

Displaying results 1241 - 1250 of 4246 in total
  1. Drug

    Acarbose

    go.drugbank.com/drugs/DB00284
    ApprovedInvestigational

    Acarbose is a complex oligosaccharide that acts as an inhibitor of several enzymes responsible for the breakdown of complex carbohydrates in the intestines.

  2. Drug

    Sutimlimab

    go.drugbank.com/drugs/DB14996
    ApprovedInvestigational

    [A245159] Pharmacologic strategies have included the targeting of B-cells with agents like [rituximab], as well as targeting of the complement system with drugs like [eculizumab], an anti-C5 mAb, and [ … In addition to non-pharmacological strategies, such as counseling patients to keep warm and the use of red blood cell transfusions, approximately 70% of patients require pharmacological treatment.

  3. Drug

    Factor IX Complex (Human)

    go.drugbank.com/drugs/DB11330
    ApprovedInvestigational

    Also known as prothrombin complex concentrate, products containing this complex often include Factor IX (antihemophilic factor B), Factor II (prothrombin), Factor X (Stuart-Prower Factor), and low levels … As the product Kcentra, Factor IX Complex is also indicated for the urgent reversal of acquired coagulation factor deficiency induced by Vitamin K antagonist (VKA, e.g., warfarin) therapy in adult patients

  4. Drug

    Doxepin

    go.drugbank.com/drugs/DB01142
    ApprovedInvestigational

    [L5977] Doxepin was developed by Pfizer and FDA approved in 1969 as an antidepressant.[L5971] However, in 2010 it was approved for the treatment of insomnia. … [T559] It is a tertiary amine that can be presented as (E) and (Z) stereoisomers with the (Z) stereoisomer corresponding to [cidoxepin]. Doxepin commonly produces a 5:1 (E):(Z) racemic mixture.

  5. Drug

    Esomeprazole

    go.drugbank.com/drugs/DB00736
    ApprovedInvestigational

    [A177571] Rapid discontinuation of PPIs such as esomeprazole may cause a rebound effect and a short term increase in hypersecretion. … Esomeprazole has been shown to inhibit acid secretion to a similar extent as [DB00338], without any significant differences between the two compounds _in vitro_.

  6. Drug

    Temafloxacin

    go.drugbank.com/drugs/DB01405
    ApprovedWithdrawn

    It was first approved for use in the U.S. market in 1992, but was withdrawn shortly due to the reports of serious adverse reactions, such as allergic reactions and hemolyric anemia, resulting in three

  7. Drug

    Zalcitabine

    go.drugbank.com/drugs/DB00943
    ApprovedWithdrawn

    The compound is a potent inhibitor of HIV replication at low concentrations, acting as a chain-terminator of viral DNA by binding to reverse transcriptase.

  8. Drug

    Fosamprenavir

    go.drugbank.com/drugs/DB01319
    ApprovedInvestigational

    Fosamprenavir is a prodrug of amprenavir, an inhibitor of human immunodeficiency virus (HIV) protease.

  9. Drug

    Maftivimab

    go.drugbank.com/drugs/DB15899
    ApprovedInvestigational

    [A222078] INMAZEB™, formerly referred to as REGN-EB3, combines the three humanized IgG1κ mAbs Maftivimab (REGN 3479), [Odesivimab] (REGN 3471), and [Atoltivimab] (REGN 3470) in equimolar proportions

  10. Target

    Epithelial sodium channel subunit alpha

    go.drugbank.com/bio_entities/BE0000190
    TargetTransporterHumans

    This is one of the three pore-forming subunits of the heterotrimeric epithelial sodium channel (ENaC), a critical regulator of sodium balance and fluid homeostasis (PubMed:30251954, PubMed:32729833, PubMed:8023962, PubMed:8278374, PubMed...

    Synonyms: Alpha-NaCH